Related Experiment Videos
Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy
C V Ram1, D Gonzalez, P Kulkarni
1Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas 75235-9030.
Insights
Alpha-adrenergic inhibitor prazosin effectively reversed left ventricular hypertrophy in hypertensive patients. This treatment significantly reduced blood pressure and left ventricular mass, offering clinical benefits beyond blood pressure control.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a common, detrimental consequence of chronic hypertension.
- While initially adaptive, progressive LVH increases cardiovascular morbidity and mortality.
- Reversal of LVH may offer significant clinical benefits for hypertensive patients.
Purpose of the Study:
- To investigate the efficacy of prazosin, an alpha-adrenergic inhibitor, in reversing left ventricular hypertrophy.
- To assess factors beyond blood pressure control in the regression of LVH.
- To evaluate the impact of prazosin monotherapy on blood pressure and left ventricular mass.
Main Methods:
- Utilized [123I]phenylpentadecanoic acid myocardioscintigraphy, a novel technique, to measure left ventricular mass.
- Administered prazosin monotherapy to patients with moderate-to-severe hypertension.
- Monitored changes in systolic and diastolic blood pressure and left ventricular mass.
Main Results:
- Prazosin monotherapy resulted in significant reductions in both systolic and diastolic blood pressure.
- Significant regression of left ventricular hypertrophy was observed in the patient group.
- Demonstrated that factors other than blood pressure severity influence LVH progression.
Conclusions:
- Alpha-adrenergic inhibition with prazosin effectively reverses left ventricular hypertrophy.
- Prazosin offers clinical benefits in hypertensive patients by reducing both blood pressure and left ventricular mass.
- Suggests targeted pharmacological approaches beyond general blood pressure lowering are crucial for managing LVH.
Abstract:
Left ventricular hypertrophy is a common consequence of chronic hypertension. Although the hypertrophic response can be considered an adaptive mechanism in the initial stages, its progression is associated with increased cardiovascular morbidity and mortality rates. Therefore, reversal of left ventricular hypertrophy may provide considerable clinical benefits to hypertensive patients. Although treatment of hypertension per se is important, blood pressure alone may not explain the course of the hypertrophic process. Not all antihypertensive drugs cause a reversal of hypertrophy, though they may produce equal effects on blood pressure. Factors other than the severity of blood pressure may play a role in the genesis of left ventricular hypertrophy. Adrenergic inhibitors cause its regression, whereas direct vasodilators may promote progression. In this study, therapy with the alpha-adrenergic inhibitor prazosin resulted in significant regression of left ventricular hypertrophy in a group of patients with moderate-to-severe hypertension. This study utilized a new technique--[123I]phenylpentadecanoic acid myocardioscintigraphy--to measure the left ventricular mass. In this study, it was shown that monotherapy with prazosin produced significant relative reductions in systolic and diastolic blood pressure, along with significant reductions in left ventricular mass.